Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Operations (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Cash from Operations for 8 consecutive years, with 71914000.0 as the latest value for Q1 2026.

  • Quarterly Cash from Operations fell 17.72% to 71914000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 260292000.0 through Feb 2026, down 35.77% year-over-year, with the annual reading at 249465000.0 for FY2025, 44.55% down from the prior year.
  • Cash from Operations for Q1 2026 was 71914000.0 at Nurix Therapeutics, down from 67832000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 26689000.0 in Q4 2023, with the low at 71914000.0 in Q1 2026.
  • Average Cash from Operations over 5 years is 43243235.29, with a median of 42630000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations plummeted 629.37% in 2022, then skyrocketed 170.32% in 2023.
  • Over 5 years, Cash from Operations stood at 37955000.0 in 2022, then surged by 170.32% to 26689000.0 in 2023, then tumbled by 282.66% to 48751000.0 in 2024, then tumbled by 39.14% to 67832000.0 in 2025, then dropped by 6.02% to 71914000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 71914000.0, 67832000.0, and 57385000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.